case_images: PMC5586731_01
case_images: Axial MR images show a 5 x 5 x 4 cm well-defined solid mass. a Gadolinium-enhanced MR images demonstrate a well-defined, uniformly enhanced lesion (arrows) originating from the medial aspect of the spleen during the hepatic venous phase. b Axial T2-weighted HASTE image following the administration of ferumoxide contrast agent demonstrates a splenic lesion (arrows) with a decreased signal intensity.
case_images: mpp-0022-0301-g01.jpg
case_images: PMC5586731_01_mpp-0022-0301-g01.jpg
case_images: F1
case_images: The lesion demonstrated a diffuse heterogeneous enhancement on early images obtained after the administration of gadopentetate dimeglumine (Magnevisth, Bayer Schering, Germany) contrast medium at a flow rate of 10 ml/15 s and became more uniformly enhanced on the portal venous phase and hepatic parenchymal phase (fig. 1a) on T1-weighted images. The lesion showed mild hypointensity on T2-weighted images. MRI study with biphasic infusion (2 ml/min for 10 min and 4 ml/min for 20 min) and at a dose of 15 mmol Fe/kg of glucose 5% ferumoxide (Endoremh, Guerbet, France) contrast agent demonstrated a splenic lesion with a decreased signal intensity on a T2-weighted half-Fourier acquisition single-shot turbo spin-echo (HASTE) image which is the same intensity as liver parenchyma (fig. 1b).